词条 | Red yeast rice |
释义 |
Red yeast rice ({{zh|s=红曲米|t=紅麴米|p=hóng qū mǐ|l=red yeast rice}}), red rice koji Red yeast rice is what is referred to as a "koji" in Japanese, meaning "grain or bean overgrown with a mold culture", a food preparation tradition going back to ca. 300 BC. In both the scientific and popular literature in English that draws principally on Japanese, red yeast rice is most often referred to as "red rice koji".[1] English language articles favoring Chinese literature sources prefer the translation "red yeast rice." ProductionRed yeast rice is produced by cultivating the yeast species Monascus purpureus on rice. The rice is first soaked in water until the grains are fully saturated. The raw soaked rice can then either be directly inoculated or it can be steamed for the purpose of sterilizing and cooking the grains prior to inoculation. Inoculation is done by mixing either M. purpureus spores or powdered red yeast rice together with the rice that is being treated. The mix is then incubated in an environment around room temperature for 3–6 days. During this period of time, the rice should be fully cultured with M. purpureus, with each rice grain turning bright red in its core and reddish purple on the outside.[2] The fully cultured rice is then either sold as the dried grain, or cooked and pasteurized to be sold as a wet paste, or dried and pulverized to be sold as a fine powder. China is the world's largest producer of red yeast rice, but European companies have entered the market.[3] UsesCulinaryRed yeast rice is used to color a wide variety of food products, including pickled tofu, red rice vinegar, char siu, Peking Duck, and Chinese pastries that require red food coloring. It is also traditionally used in the production of several types of Chinese huangjiu (Shaoxing jiu), and Japanese sake (akaisake), imparting a reddish color to these wines.[4] Although used mainly for its color in cuisine, red yeast rice imparts a subtle but pleasant taste to food and is commonly used in the cuisine of the Fujian province of China.[5] Red yeast rice (angkak in Filipino) is also used widely in the Philippines to traditionally color and preserve certain dishes like fermented shrimp (bagoong alamang), burong isda (fermented rice and fish), and balao-balao (fermented rice and shrimp).[6][7][8] Traditional Chinese medicineIn addition to its culinary use, red yeast rice is also used in Chinese herbology and traditional Chinese medicine. Its use has been documented as far back as the Tang Dynasty in China in 800 AD. It is taken internally to invigorate the body, aid in digestion, and revitalize the blood.[9] A more complete description is in the traditional Chinese pharmacopoeia, Ben Cao Gang Mu-Dan Shi Bu Yi, from the Ming Dynasty (1378–1644).[10] Red yeast rice and 'statin' drugsIn the late 1970s, researchers in the United States and Japan were isolating lovastatin from Aspergillus and monacolins from Monascus, respectively, the latter being the same fungus used to make red yeast rice but cultured under carefully controlled conditions. Chemical analysis soon showed that lovastatin and monacolin K are identical. The article "The origin of statins" summarizes how the two isolations, documentations and patent applications were just months apart.[11] Lovastatin became the patented, prescription drug Mevacor.[12] Red yeast rice went on to become a contentious, non-prescription dietary supplement in the United States and other countries. Lovastatin and other prescription 'statin' drugs inhibit cholesterol synthesis by blocking action of the enzyme HMG-CoA reductase. As a consequence, circulating total cholesterol and LDL-cholesterol are lowered by 24-49% depending on the statin and dose.[13] Different strains of Monascus fungus will produce different amounts of monacolins. The 'Went' strain of Monascus purpureus (purpureus = dark red in Latin), when properly fermented and processed, will yield a dried red yeast rice powder that is approximately 0.4% monacolins, of which roughly half will be monacolin K (identical to lovastatin). Monacolin content of a red yeast rice product is described in a 2008 clinical trial report.[14] Regulatory restrictionsThe US Food and Drug Administration (FDA) position is that red yeast rice products that contain monacolin K, i.e., lovastatin, are identical to a drug and, thus, subject to regulation as a drug. In 1998, the FDA initiated action to ban a product (Cholestin) containing red yeast rice extract. The U.S. District Court in Utah allowed the product to be sold without restriction. This decision was reversed on appeal to the U.S. Court of Appeals. (Moore, 2001) (see External links: PDRhealth). Thereafter, the FDA sent Warning Letters to companies selling red yeast rice. The product disappeared from the market for a few years. In 2003, red yeast rice products began to reappear in the U.S. market. In 2007, the FDA sent Warning Letters to two dietary supplement companies. One was making a monacolin content claim about its RYR product and the other was not, but the FDA noted that both products contained monacolins. Both products were withdrawn.[15] In this press release the FDA stated that consumers should "… not buy or eat red yeast rice products … may contain an unauthorized drug that could be harmful to health." The rationale for "… harmful to health …" was that consumers might not understand that the dangers of monacolin-containing red yeast rice might be the same as those of prescription statin drugs.[15] A products analysis report from 2010 tested 12 products commercially available in the US and reported that per 600 mg capsule, total monacolins content ranged from 0.31 to 11.15 mg.[17] A 2017 study tested 28 brands of red yeast rice supplements purchased from US retailers, stating "the quantity of monacolin K varied from none to prescription strength [...]"[16] Many of these avoid FDA regulation by not having any appreciable monacolin content. Their labels and websites say no more than "fermented according to traditional Asian methods" or "similar to that used in culinary applications." The labeling on these products often says nothing about cholesterol. If they do not contain lovastatin, do not claim to contain lovastatin, and do not make a claim to lower cholesterol, they are not subject to FDA action. Two reviews confirm that the monacolin content of red yeast rice dietary supplements can vary over a wide range, with some containing negligible monacolins.[17][18] Clinical evidenceThe amount typically used in clinical trials is 1200–2400 mg/day of red yeast rice containing approximately 10 mg total monacolins, of which half are monacolin K. This does raise a question about the function of the other monacolins and non-monacolin compounds in the products, as the monacolin K content is lower than what is usually considered effective for lovastatin (20–80 mg/day). A meta-analysis reported LDL-cholesterol lowered by 1.02 mmol/L (39.4 mg/dL) compared to placebo. The incidence of reported adverse effects ranged from 0% to 5% and was not different from controls.[19] A second meta-analysis incorporating more recent clinical trials reported significant lowering of total cholesterol and LDL-cholesterol.[20] Within the first review,[19] the largest and longest duration trial was conducted in China: the China Coronary Secondary Prevention Study (CCSPS). Close to 5,000 post-heart attack patients were enrolled for an average of 4.5 years to receive either a placebo or a RYR product named Xuezhikang (血脂康). The test product was an ethanol extract of red yeast rice, with a monacolin K content of 11.6 mg/day. Key CCSPS results: In the treated group, risk of subsequent heart attacks was reduced by 45%, cardio deaths by 31%, and all-cause deaths by 33%.[21] The CCSPS heart attack and cardiovascular death outcomes appear to be better than what has been reported for prescription statin drugs. A 2008 review pointed out that the cardioprotective effects of statins in Japanese populations occur at lower doses than are needed in Western populations, and theorized that the low amount of monacolins found in Xuezhikang might have been more effectively athero-protective than expected in the Chinese population in the CCSPS study for the same reason.[22] SafetyThe safety of red yeast rice products has not been established, and some commercial supplements have been found to contain high levels of the toxin citrinin.[23] As commercial products will have highly variable amounts of monacolins,[23] and rarely declare this content on the label, defining risk is difficult. Ingredient suppliers have also been suspected of "spiking" red yeast rice preparations with purified lovastatin. As evidence, one published analysis reported several commercial products as being almost entirely monacolin K - which would occur if the drug lovastatin was added - rather than the expected composition of many monacolin compounds.[17] Statin drugs are known to cause muscle and liver damage. Statin-associated rhabdomyolysis can lead to kidney damage and possibly kidney failure (renal failure). This is why they are prescription drugs rather than over-the-counter, and with recommendations that the patients' physicians schedule liver function tests on a regular basis. There are reports in the literature of muscle myopathy and liver damage resulting from red yeast rice usage.[24] From a placebo-controlled trial in patients with known statin-associated myalgias, in the treated group, two patients dropped out because of myalgia, 1 for diarrhea, and 1 for dizziness. In the placebo group, one dropped out for myalgia. Creatine phosphokinase increased slightly in the treated group (from 122 to 128 IU/L) versus decreasing with placebo (117 to 101 IU/L), but the shifts were not statistically significant. Subjective muscle pain scores were similar for the two groups.[25] "The potential safety signals of myopathies and liver injury raise the hypothesis that the safety profile of RYR is similar to that of statins. Continuous monitoring of dietary supplements should be promoted to finally characterize their risk profile, thus supporting regulatory bodies for appropriate actions."[26] The European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources added to Food concluded that when red yeast rice preparations contained monacolins, the Panel was unable to identify an intake that it could consider as safe. The reason given was case study reports of severe adverse reactions to products containing monacolins at amounts as low as 3 mg/day.[27] Red yeast rice is not recommended during pregnancy or breast-feeding.[28] See also{{Portal|Fungi}}
References1. ^Shurtleff W, Aoyagi A (2012). History of Koji - Grains and/or Beans Overgrown with a Mold Culture (300 BCE to 2012). Lafayette, California: Soyinfo Center. 2. ^{{cite journal |vauthors=Patakova P |title=Monascus secondary metabolites: production and biological activity |journal=J. Ind. Microbiol. Biotechnol. |volume=40 |issue=2 |pages=169–181 |date=2013 |pmid=23179468 |doi=10.1007/s10295-012-1216-8 |url=}} 3. ^{{cite web |url=https://www.nutraingredients.com/Article/2012/07/18/Gee-Lawson-enters-China-dominated-red-yeast-rice-supply# |title=Gee-Lawson-enters-China-dominated-red-yeast-rice-supply |last=Starling |first=Shane |date=2012 |website=NutraIngredients |access-date=19 December 2018}} 4. ^{{cite web|title=Gauntner's Japan Times Stories |year=2001 |last=Gauntner |first=John |url=http://www.esake.com/Knowledge/Newsletter/JT/JT2001/jt2001_23.html |website=The Japan Times |access-date=28 December 2018}} 5. ^{{citation|title=Food plants of China |first=Shiu-ying |last=Hu |publisher=Chinese University Press |year=2005}} 6. ^{{cite book|first1=Wonnop |last1=Visessanguan|first2=Siriporn|last2=Chaikaew|editor1-first=Prabir K.|editor1-last= Sarkar|editor2-first=M.J. Robert |editor2-last= Nout|title =Handbook of Indigenous Foods Involving Alkaline Fermentation|chapter=Shellfish Products|publisher =CRC Press|year =2014|pages=212–213|isbn =9781466565302|url =https://books.google.com.ph/books?id=PVfSBQAAQBAJ&lpg=PP1&pg=PA212#v=onepage&q&f=false}} 7. ^{{cite book|first1=J.F. |last1=Redhead|title =Utilization of Tropical Foods: Animal products|publisher =Food & Agriculture Organization of the United Nations|series =FAO Food and Nutrition Paper|year =1990|page=35|isbn =9789251028780|url =https://books.google.com.ph/books?id=yVtMmDt3i4MC&lpg=PP1&pg=PA35#v=onepage&q&f=false}} 8. ^{{cite book|first1=Priscilla C.|last1= Sanchez|title =Philippine Fermented Foods: Principles and Technology|chapter =Lactic-Acid-Fermented Fish and Fishery Products|publisher =University of the Philippines Press|year =2008|page=264|isbn = 9789715425544|url =https://books.google.com.ph/books?id=smfr-KYgtWkC&lpg=PP1&pg=PT10#v=onepage&q&f=false}} 9. ^Erdogrull O, Azirak S. (2004). "Review of the studies on the red yeast rice (Monascus purpureus)". Turkish Electronic J Biotech. 2: 37-49. 10. ^{{cite journal|vauthors=Zhao Z, Liang Z |title=The Original Source of Modern Research on Chinese Medicinal Materials: Bencao Texts |journal=J Altern Complement Integr Med |volume=3 |issue= |pages=045 |year=2017 |url= |DOI=10.24966/ACIM-7562/100045}} 11. ^{{cite journal |author=Endo A |title=The origin of the statins. 2004 |journal=Atheroscler Suppl |volume=5 |issue=3 |pages=125–130 |date=2004 |pmid= 15531285|doi=10.1016/j.atherosclerosissup.2004.08.033 |url=}} 12. ^{{cite web |url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=11188&f=G&l=50&d=PTXT&s1=lovastatin&p=224&OS=lovastatin&RS=lovastatin |title=Novel HMG-CoA reductase inhibitors |last1=Duggan |first1=Mark|last2=Hartman |first2=George D |date=15 August 1989 |website= US Patent and Trademark Office |access-date=13 January 2019}} 13. ^{{cite journal |vauthors=Edwards JE, Moore RA |title=Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials |journal=BMC Fam Pract |volume=4|pages=18 |date=2003 |pmid=14969594 |pmc=317299 |doi=10.1186/1471-2296-4-18 |url=}} 14. ^{{cite journal |vauthors=Becker DJ, Gordon RY, Morris PB, et al |title=Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial |journal=Mayo Clin. Proc. |volume=83 |issue=7 |pages=758–764 |date=2008 |pmid=18613992 |doi= 10.4065/83.7.758|url=}} 15. ^1 {{cite web|author=FDA| title=FDA Warns Consumers to Avoid Red Yeast Rice Products Promoted on Internet as Treatments for High Cholesterol| url= http://www.fda.gov/bbs/topics/NEWS/2007/NEW01678.html |date=August 9, 2007 |archive-url=https://wayback.archive-it.org/7993/20170111224458/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm108962.htm |archive-date=Jan 11, 2017}} 16. ^{{cite journal |vauthors=Cohen PA, Avula B, Khan IA |title=Variability in strength of red yeast rice supplements purchased from mainstream retailers |journal=Eur J Prev Cardiol |volume=24 |issue=13 |pages=1431–1434 |date=2017 |pmid=28641460 |doi=10.1177/2047487317715714 |url=}} 17. ^1 {{cite journal |vauthors=Li YG, Zhang F, Wang ZT, Hu ZB |title=Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry |journal=J Pharm Biomed Anal |volume=35 |issue=5 |pages=1101–1112 |date=2004 |pmid=15336357 |doi=10.1016/j.jpba.2004.04.004 |url=}} 18. ^{{cite journal |vauthors=Heber D, Lembertas A, Lu QY, Bowerman S, Go VL |title=An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents |journal=J Altern Complement Med |volume=7 |issue=2 |pages=133–139 |date=2001 |pmid=11327519 |doi=10.1089/107555301750164181 |url=}} 19. ^1 {{cite journal |vauthors=Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE |title=Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis |journal=Atherosclerosis |volume=240 |issue=2 |pages=415–423 |year=2015 |pmid=25897793 |doi=10.1016/j.atherosclerosis.2015.04.004 |url=}} 20. ^{{cite journal |vauthors=Peng D, Fong A, Pelt AV |title=Original Research: The Effects of Red Yeast Rice Supplementation on Cholesterol Levels in Adults |journal=Am J Nurs |volume=117 |issue=8 |pages=46–54 |date=2017 |pmid=28749884 |doi=10.1097/01.NAJ.0000521973.38717.2e |url=}} 21. ^{{cite journal |author=Lu ZL |title=[China coronary secondary prevention study (CCSPS)] |language=Chinese |journal=Zhonghua Xin Xue Guan Bing Za Zhi |volume=33 |issue=2 |pages=109–115 |date=2005 |pmid=15924803 |doi=|author2=Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang}} 22. ^{{cite journal |vauthors=Ong HT, Cheah JS |title=Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics |journal=Chin. Med. J. |volume=121 |issue=16 |pages=1588–1594 |date=2008 |pmid=18982874 |doi= |url=}} 23. ^1 2 {{cite journal |vauthors=Gordon RY, Cooperman T, Obermeyer W, Becker DJ |title = Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products: Buyer Beware! |journal = Archives of Internal Medicine |volume=170 |issue=19 |pages = 1722–1727 |year=2010 |pmid = 20975018 |doi = 10.1001/archinternmed.2010.382}} 24. ^{{cite journal |vauthors=Philibert C, Bres V, Jean-Pastor MJ, Guy C, Lebrun-Vignes B, Robin P, Pinzani V, Hillaire-Buys D |title=[Red yeast-rice-induced muscular injuries: Analysis of French pharmacovigilance database and literature review] |language=French |journal=Thérapie |volume= |issue= |pages= |year=2016 |pmid=28277227 |doi=10.2515/therapie/2015053 |url=}} 25. ^{{cite journal |vauthors=Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ |title=Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial |journal=Ann. Intern. Med. |volume=150 |issue=12 |pages=830–839 |date=2009 |pmid=19528562 |doi= 10.7326/0003-4819-150-12-200906160-00006|url=}} 26. ^{{cite journal |vauthors=Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F |title=Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system |journal=Br J Clin Pharmacol |volume=83 |issue=4 |pages=894–908 |date=2017 |pmid=28093797 |pmc=5346868 |doi=10.1111/bcp.13171 |url=}} 27. ^{{cite journal|vauthors=Younes M, Aggett P, Aguilar F, et al |title=Scientific opinion on the safety of monacolins in red yeast rice |journal=EFSA Journal |volume=16 |issue=8 |pages=5368 |year=2018 |url=https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2018.5368 |DOI=10.2903/j.efsa.2018.5368}} 28. ^{{cite web|title=Red Yeast Rice |year=2013 |url=https://nccih.nih.gov/health/redyeastrice |website=NIH: National Center for Complementary and Integrative Health |access-date=28 December 2018}} External links{{Commons category}}
6 : Traditional Chinese medicine|Dietary supplements|Food colorings|Medicinal fungi|Medical controversies|Fermented foods |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。